Stock ALPMY ASTELLAS PHARMA INC.
Add to a list
To use this feature you must be a member
Log inSign up

Astellas Pharma Inc. Stock OTC Markets

Equities

ALPMY

US04623U1025

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 03:59:59 2024-07-12 pm EDT 		5-day change 1st Jan Change
10.46 USD +1.26% Intraday chart for Astellas Pharma Inc. +4.39% -12.10%
Jul. 02 Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer CI
Jun. 03 US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab MT

Financials

Sales 2025 * 1,685B 10.66B Sales 2026 * 1,771B 11.2B Capitalization 2,971B 18.79B
Net income 2025 * 61.53B 389M Net income 2026 * 137B 866M EV / Sales 2025 * 2.1 x
Net Debt 2025 * 563B 3.56B Net Debt 2026 * 443B 2.8B EV / Sales 2026 * 1.93 x
P/E ratio 2025 *
48.3 x
P/E ratio 2026 *
21.7 x
Employees 14,754
Yield 2025 *
4.49%
Yield 2026 *
4.75%
Free-Float 98.84%
More Fundamentals * Assessed data

Chart Astellas Pharma Inc.

Dynamic Chart

Latest news about Astellas Pharma Inc.

Astellas Pharma Inc. Announces the Center for Drug Evaluation of the China National Medical Products Administration Approves Xtandi (Enzalutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer CI
US FDA Acknowledges Astellas Pharma's Resubmission of Biologics License Application for Zolbetuximab MT
U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.? Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date CI
Astellas Announces Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies CI
Strong Cresemba(R) (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea DJ
Astellas Unveils New, State-Of-The-Art, $90 Million West Coast Innovation Center in the South San Francisco Biotech Corridor CI
Poseida Therapeutics to Receive Up to $600 Million in Cancer Gene Therapy Research, Development Deal With Xyphos MT
Malin Corp investee signs agreement with Astellas Pharma AN
Poseida Therapeutics Shares Rise 18% After Licensing Deal With Xyphos Biosciences DJ
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion RE
Transcript : Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024
Astellas Pharma Inc. Declares Year End Dividend for the Year Ended March 31, 2023 and Provides Interim and Year End Dividend Guidance for the Fiscal Year 2024 CI
Astellas Pharma Inc. Provides Consolidated Earnings Guidance on Full Basis for the Full-Year 2024 CI
Astellas Pharma Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Astellas Pharma Inc. Announces Board and Committee Retirements CI
More news

Latest transcript on Astellas Pharma Inc.

Logo Astellas Pharma Inc.
Astellas Pharma Inc., 2024 Earnings Call, Apr 25, 2024
More transcripts

Analyst Recommendations on Astellas Pharma Inc.

Jefferies Adjusts Astellas Pharma’s Price Target to 2,100 Yen From 2,200 Yen, Keeps at Buy MT
Jefferies Adjusts Astellas Pharma’s Price Target to 2,200 Yen From 2,400 Yen, Keeps at Buy MT
Jefferies Upgrades Astellas Pharma to Buy From Hold, Keeps Price Target at 2,400 Yen MT
Jefferies Adjusts Astellas Pharma's Price Target to 2,400 Yen From 2,300 Yen, Keeps at Buy MT
Jefferies Adjusts Astella Pharma’s Price Target to 2,300 Yen From 2,200 Yen, Keeps at Buy MT
More recommendations

Press releases Astellas Pharma Inc.

Astellas Confirms Unfavorable District Court Decision Concerning its Motion for a Preliminary Injunction against Lupin and Zydus Generic Versions of MyrbetriqTM AQ
U.S. FDA Accepts Astellas' Supplemental New Drug Application for IZERVAY (avacincaptad pegol intravitreal solution) for Geographic Atrophy AQ
Astellas VYLOY Approved in Japan for Treatment of Gastric Cancer AQ
Iveric Bio - Astellas Receives Permanent J-code for IZERVAY for Geographic Atrophy AQ
Astellas Receives Positive CHMP Opinion for XTANDI in Additional Recurrent Early Prostate Cancer Treatment Setting AQ
More press releases

News in other languages on Astellas Pharma Inc.

MÄRKTE ASIEN/Freundlich - Yen lotet neue Tiefs aus
MIDDAY BRIEFING - Unternehmen und Märkte
MÄRKTE ASIEN/Börsen stecken Eskalation im Nahen Osten gut weg
Aktien Asien/Pazifik: Eskalation im Nahen Osten drückt die Kurse - CSI legt zu
Bayer plant Zulassungsantrag für neues Mittel gegen Wechseljahrsbeschwerden
More news

Quotes and Performance

1 day+1.26%
1 week+4.39%
Current month+6.09%
1 month+9.99%
3 months+9.53%
6 months-13.41%
Current year-12.10%
More quotes

Highs and lows

1 week
9.81
Extreme 9.81
10.51
1 month
9.35
Extreme 9.35
10.51
Current year
9.15
Extreme 9.15
12.71
1 year
9.15
Extreme 9.15
15.90
3 years
9.15
Extreme 9.15
18.18
5 years
9.15
Extreme 9.15
18.46
10 years
9.15
Extreme 9.15
19.40
More quotes

Managers and Directors - Astellas Pharma Inc.

Managers TitleAgeSince
Naoki Okamura CEO
 Chief Executive Officer 61 86-03-31
Kitamura Atsushi DFI
 Director of Finance/CFO 52 Oct. 31
Kenji Yasukawa CHM
 Chairman 64 86-03-31
Members of the board TitleAgeSince
Kenji Yasukawa CHM
 Chairman 64 86-03-31
Naoki Okamura CEO
 Chief Executive Officer 61 86-03-31
Tatsuro Ishizuka BRD
 Director/Board Member 68 19-05-31
More insiders

Quotes

Date Price Change Volume
24-07-12 10.46 +1.26% 136,217
24-07-11 10.33 +2.28% 243,741
24-07-10 10.1 +0.40% 120,148
24-07-09 10.06 +0.65% 351,421
24-07-08 9.995 -0.25% 114,848

Delayed Quote OTC Markets, July 12, 2024 at 03:59 pm EDT

More quotes

Company Profile

Astellas Pharma Inc. specializes in the research, development, manufacturing and marketing of pharmaceutical products. Products are especially for immune diseases, infectious diseases, skin diseases, cancer and urologic disorders. Net sales are distributed geographically as follows: Japan (28.8%), Americas (34.5%) and others (36.7%).
Sector
Pharmaceuticals
Calendar
2024-08-01 - Q1 2024 Earnings Release
Related indices
Nikkei 225
More about the company

Income Statement Evolution

More financial data

Ratings for Astellas Pharma Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
1,657 JPY
Average target price
1,845 JPY
Spread / Average Target
+11.37%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 854B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 636B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 324B
ABBVIE INC. Stock AbbVie Inc.
+9.87% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 247B
ROCHE HOLDING AG Stock Roche Holding AG
+4.21% 230B
NOVARTIS AG Stock Novartis AG
+17.90% 228B
AMGEN INC. Stock Amgen Inc.
+14.86% 177B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4503 Stock
  4. ALPMY Stock